₹22
*Average Price as per 9 December, 2024
Fundamentals
FACE VALUE
1
BOOK VALUE
1.89
NO OF SHARES
11547619047
EPS
-2.2
SALES
5664.29
INDUSTRY PE
0
DIVIDEND
0
DIVIDEND YIELD
0
PE
-3.68
PB
4.29
PS
1.65
MARKET CAP
9353.57
EQUITY
1154
PAT
-2533.51
MESSAGE
2023-24
OVERVIEW
PharmEasy is a consumer healthcare “super app” that provides consumers with on-demand, home delivered access to a wide range of prescription, OTC pharmaceutical, other consumer healthcare products, comprehensive diagnostic test services, and teleconsultations thereby serving their healthcare needs.
API Holdings Ltd aka Pharmeasy is India’s largest digital healthcare platform (based on GMV of products and services sold for the year ended March 31, 2021), according to RedSeer Report.
Pharmeasy operate an integrated, end-to-end business that aims to provide solutions for the healthcare needs of consumers across the following critical stages -
A. providing digital tools and information on illness and wellness,
B. offering teleconsultation,
C. offering diagnostics and radiology tests, and
D. delivering treatment protocols including products and devices
2015: PharmEasy was founded by Dharmil Sheth and Dhaval Shah in Mumbai, India
2016: Raised $5 million in Series A funding led by Bessemer Venture Partners
2017: Secured $18 million in two rounds of Series B funding from Bessemer Venture Partners
2018: Raised $77.23 million across two Series C funding rounds from Eight Roads Ventures India, F-Prime Capital
2019: Raised $220 million in Series D funding from Temasek Holdings
2020: Merger of Medlife with PharmEasy
2021:
2022: PharmEasy withdrew its IPO plans and went with rights issue
Siddharth Shah: Co-Founder, Managing Director and Chief Executive Officer
Dharmil Sheth: Co-Founder and Whole-time Director
Dr. Dhaval Shah: Co-Founder
Harsh Parekh: Co-Founder and Whole-time Director
Hardik Dedhia: Co-Founder
INSIGHT
In Crs
Particulars | 31st March, 2023 | 31st March, 2022 |
Revenue | 6700 | 5781 |
EBITDA | -1365 | -2300 |
PBT | -5197 | -3971 |
PAT | -5212 | -3993 |
API Holdings, the parent company of online pharmacy start-up PharmEasy, on Monday received approval from Sebi to raise Rs 6,250 crore through an initial public offering (IPO).
Pharmeasy was last valued at $5.6 billion (Rs 42,197.79 crore) in a Rs 2,635.22-crore pre-IPO round in October 21.
On 29 November 2021 API Holding Limited issue equity shares of FV Rs 1 per shares @ 4.20 per shares (Details are given below)
The Indian e-pharma industry is experiencing explosive growth, with a projected CAGR ranging from 44% to 63%.
Here's a breakdown of the promising outlook with specific figures:
Market size: The e-pharmacy market in India was valued around $512 million in 2018 and is expected to reach anywhere from $3.6 billion by 2022 to $4.5 billion by 2025.
Revenue growth: E-pharmacies are expected to see their revenue grow at a significant rate, with estimates suggesting a 54% CAGR over the next 4 years.
This translates to capturing around 5% of the total pharmaceutical sector revenue. These figures paint a bright picture for e-pharma companies like PharmEasy. The industry is attracting significant investment, with funding of $700 million secured in 2020 alone.
PharmEasy's parent company, API Holdings, secured its most recent funding in April 2024.
Amount raised: $216 million (Rs 1,804 crore)
Investors: The round was led by Manipal Education and Medical Group (MEMG) along with participation from existing investors like Prosus, Temasek, and 360 One.Impact:
This funding came with a significant valuation drop of around 90% compared to PharmEasy's peak valuation of $5.6 billion in 2021. The current valuation is estimated to be around $710 million.
API Holdings is a holding company that owns 71.18% of Thyrocare Technologies Ltd, making Thyrocare Technologies Ltd a subsidiary of API Holdings.
API Holdings owns 3,76,56,092( AS PER BALANCE SHEET FY 22-23) equity shares of Thyrocare Technologies Ltd, and the current market price (CMP) of the share is 751,(AS ON 24/07/2024) equivalent to 2827.9 Crores
SECONDARY NAME
ISIN
CDSL
NSDL
INDUSTRY
SECTOR (READ ONLY)
SHARE HOLDINGS
Name of Shareholder | Holdings |
---|---|
Naspers Ventures BV | 13.24 % |
Macritchie Investments Pte. Ltd | 11.93 % |
Surbhi Singh jointly with Universal Trustees Private Limited | 6.1 % |
TP G Growth V SF Markets Pvt Ltd | 7.32 % |
Evermed Holdings Pte. Ltd | 6.45 % |
We're different. SB NRI is the first of it's kind platform built for NRIs offering digital Investment plans.
Schedule a CallTrusted by 1,000s of NRIs spread across the Globe